Login to Your Account



ODAC Panel Backs Celgene's Single Study Data On Revlimid

By Aaron Lorenzo


Thursday, September 15, 2005
BETHESDA, Md. - The FDA's Oncologic Drugs Advisory Committee voted 10-5 in favor of approving Celgene Corp.'s Revlimid (lenalidomide) for myelodysplastic syndromes (MDS) in transfusion-dependent patients with a 5q-deletion chromosomal abnormality. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription